American National Registered Investment Advisor Inc. maintained its position in Mylan (NASDAQ:MYL) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,222 shares of the company’s stock at the end of the first quarter. American National Registered Investment Advisor Inc.’s holdings in Mylan were worth $555,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MYL. Kernodle & Katon Asset Management Group LLC boosted its position in Mylan by 4.7% in the third quarter. Kernodle & Katon Asset Management Group LLC now owns 2,884 shares of the company’s stock worth $110,000 after buying an additional 129 shares in the last quarter. Mosaic Family Wealth LLC boosted its position in Mylan by 12.5% in the third quarter. Mosaic Family Wealth LLC now owns 3,600 shares of the company’s stock worth $137,000 after buying an additional 400 shares in the last quarter. Oakworth Capital Inc. boosted its position in Mylan by 30.7% in the first quarter. Oakworth Capital Inc. now owns 4,255 shares of the company’s stock worth $166,000 after buying an additional 1,000 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in Mylan during the first quarter worth approximately $188,000. Finally, Mycio Wealth Partners LLC acquired a new position in Mylan during the first quarter worth approximately $200,000. Hedge funds and other institutional investors own 60.89% of the company’s stock.
Mylan (NASDAQ:MYL) traded down 0.29% during mid-day trading on Friday, hitting $37.90. The stock had a trading volume of 5,568,919 shares. The company has a 50 day moving average price of $38.91 and a 200-day moving average price of $38.68. Mylan has a one year low of $33.60 and a one year high of $50.40. The company has a market cap of $20.30 billion, a price-to-earnings ratio of 41.20 and a beta of 1.14.
Mylan (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, March 1st. The company reported $1.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.42 by $0.15. Mylan had a net margin of 2.50% and a return on equity of 22.04%. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.18 billion. During the same quarter in the previous year, the firm posted $1.22 EPS. Equities analysts expect that Mylan will post $5.28 earnings per share for the current fiscal year.
A number of research firms recently commented on MYL. Mizuho reissued a “buy” rating and issued a $47.00 target price on shares of Mylan in a research report on Tuesday, February 28th. Leerink Swann reissued an “outperform” rating and issued a $52.00 target price on shares of Mylan in a research report on Monday, March 6th. BMO Capital Markets began coverage on Mylan in a research report on Monday, May 1st. They issued an “outperform” rating and a $50.00 target price on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $48.00 target price on shares of Mylan in a research report on Thursday, March 30th. Finally, Guggenheim reissued a “neutral” rating on shares of Mylan in a research report on Friday, March 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $51.85.
In related news, major shareholder Laboratories Abbott sold 44,000,000 shares of Mylan stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total transaction of $1,830,400,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.71% of the company’s stock.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).